GeneLink: Genetically Tailored Nutritional Supplements
by Hisham S. Ayoub, DMD
BioHealth Investor
There are many biotech and medical technology companies racing to bring to market a variety of drugs tailored to an individual's unique genetic makeup. Many on Wall Street are betting that these products will revolutionize medicine. Shares of Biotech companies utilizing the latest in genetic based drug manufacturing have been one of the hottest stocks over the last two decades.
Yet, genetically tailored nutritional and dermatological supplements have flown under the radar. On Tuesday, GeneLink (GNLK.OB), a little known company which manufactures and sells personal gene testing kits announced that it has entered into an agreement with Solgar Vitamin and Herb, a nutritional supplement manufacturer and distributor.
According to the press release under the terms of the agreement,
and,
Now let's think about this for a minute; How great would it be to test your genetic makeup and based on the results, say maybe you are prone to dehydration or weak joints, or have a chronic condition such as diabetes or arthritis, a supplement is formulated optimally for your specific needs?
If GeneLink management is smart, and promotes the product extensively, then I could see Nutrigenomx being a great revenue producer for the company, which is worth a miniscule $9 million on the open market.
The company also markets Dermagenetics, a proprietory gene-based line of skin care products. According to the company's website Dermagenetics Skin Care System "is the first and only clinically tested, scientifically proven customized skin care system genetically matched to an individual’s skin’s DNA".
T
his tiny stock could still reap huge rewards for risk loving investors, even though it has more than quadrupled over the last 52 weeks. The tiny market cap, coupled with a low float of 30 million shares and insiders holding 30% of the outstanding shares, all add up to a potentially lucrative investment.
Of course, with any tiny penny stock, actually with all stocks for that matter, especially these days, investors must be carefull. Penny stocks are easily manipulated by traders and market makers no matter the business activities of the company.
Still, I personally am betting on a great year in 2008 as sales of Nutrigenomx commence. I purchased shares three weeks ago at $0.15 for a quick trade based solely on volume spikes and stock movement. But after Tuesday's announcement I am looking to hold GeneLink stock well into 2008.
BioHealth Investor.com
______________________
BioHealth Investor
There are many biotech and medical technology companies racing to bring to market a variety of drugs tailored to an individual's unique genetic makeup. Many on Wall Street are betting that these products will revolutionize medicine. Shares of Biotech companies utilizing the latest in genetic based drug manufacturing have been one of the hottest stocks over the last two decades.
Yet, genetically tailored nutritional and dermatological supplements have flown under the radar. On Tuesday, GeneLink (GNLK.OB), a little known company which manufactures and sells personal gene testing kits announced that it has entered into an agreement with Solgar Vitamin and Herb, a nutritional supplement manufacturer and distributor.
According to the press release under the terms of the agreement,
"Solgar, in 2008, will begin marketing a brand of advanced genetically-guided nutritional supplements, called Nutrigenomx™, utilizing GeneLink’s Nutritional System™ which includes its patented DNA Collection Kit and Genetic Compass™ reporting system".
and,
"GeneLink and Solgar expect to be the first companies, on a retail basis, to offer a proprietary dietary supplement system tailored to an individual’s genetic makeup".
Now let's think about this for a minute; How great would it be to test your genetic makeup and based on the results, say maybe you are prone to dehydration or weak joints, or have a chronic condition such as diabetes or arthritis, a supplement is formulated optimally for your specific needs?
If GeneLink management is smart, and promotes the product extensively, then I could see Nutrigenomx being a great revenue producer for the company, which is worth a miniscule $9 million on the open market.
The company also markets Dermagenetics, a proprietory gene-based line of skin care products. According to the company's website Dermagenetics Skin Care System "is the first and only clinically tested, scientifically proven customized skin care system genetically matched to an individual’s skin’s DNA".
T
his tiny stock could still reap huge rewards for risk loving investors, even though it has more than quadrupled over the last 52 weeks. The tiny market cap, coupled with a low float of 30 million shares and insiders holding 30% of the outstanding shares, all add up to a potentially lucrative investment.Of course, with any tiny penny stock, actually with all stocks for that matter, especially these days, investors must be carefull. Penny stocks are easily manipulated by traders and market makers no matter the business activities of the company.
Still, I personally am betting on a great year in 2008 as sales of Nutrigenomx commence. I purchased shares three weeks ago at $0.15 for a quick trade based solely on volume spikes and stock movement. But after Tuesday's announcement I am looking to hold GeneLink stock well into 2008.
BioHealth Investor.com
______________________
posted by Nico at
9:21 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home